EX-4.1 3 d863514dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 JOHNSON & JOHNSON COMPANY ORDER Pursuant to the authorization of the Board of Directors of Johnson & Johnson, a New Jersey corporation (the “Company”), in resolutions adopted on February 14, 2023, October 31, 2022 and April 25, 2024, the undersigned, being duly authorized, hereby approves the issuance of each of the series of Notes (as defined herein) of the Company, with the terms and provisions as described below, pursuant to and further subject to an Indenture (the “Indenture”), dated as of September 15, 1987, by and between the Company and The Bank of New York Mellon Trust Company, N.A. (as successor to BNY Midwest Trust Company, which succeeded Harris Trust and Savings Bank), as supplemented by the First Supplemental Indenture dated as of September 1, 1990 and the Second Supplemental Indenture dated as of November 9, 2017. TITLE OF SERIES: 2.700% Notes due 2029 (the “2.700% Notes”) 3.050% Notes due 2033 (the “3.050% Notes”) 3.350% Notes due 2037 (the “3.350% Notes”) 3.600% Notes due 2045 (the “3.600% Notes”) …
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Johnson & Johnson
JNJNYSEEQUITYCurrent
Other Events
Item 8.01 Other Events On February 26, 2025, Johnson & Johnson (the “Company”) completed the previously announced public offerings of the following: (1) €600,000,000 aggregate principal amount of 2.700% Notes due 2029 (the “2029 Notes”); (2) €700,000,000 aggregate principal amount of 3.050% Notes due 2033 (the “2033 Notes”); (3) €1,000,000,000 aggregate principal amount of 3.350% Notes due 2037 (the “2037 Notes”);…
Company context
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.
Current securities
Disclosure sections
Item 8.01Item 8.01 - Other Events
Filed exhibits (6)
EX-4.2 4 d863514dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 CUSIP NO.: 478160 DB7 PRINCIPAL AMOUNT ISIN: XS3005214104 €[ ] Common Code: 300521410 REGISTERED NO. R- JOHNSON & JOHNSON 2.700% NOTE DUE 2029 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of The Bank of New York Depository (Nominees) Limited, or such other name as requested by an authorized representative of Euroclear or Clearstream (and any payment is made to its authorized nominee or to such other entity as is requested by an authorized representative of Euroclear or Clearstream), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL as the registered owner hereof, The Bank of New York Depository (Nominees) Limited, has an interest herein. The following summary of terms is subject to the information set forth on the reverse hereof: ORIGINAL ISSUE DATE: February 26, 2025 MATURITY DATE: …
Open exhibit ↗EX-4.3 5 d863514dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 CUSIP NO.: 478160 DC5 PRINCIPAL AMOUNT ISIN: XS3005214369 €[ ] Common Code: 300521436 REGISTERED NO. R- JOHNSON & JOHNSON 3.050% NOTE DUE 2033 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of The Bank of New York Depository (Nominees) Limited, or such other name as requested by an authorized representative of Euroclear or Clearstream (and any payment is made to its authorized nominee or to such other entity as is requested by an authorized representative of Euroclear or Clearstream), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL as the registered owner hereof, The Bank of New York Depository (Nominees) Limited, has an interest herein. The following summary of terms is subject to the information set forth on the reverse hereof: ORIGINAL ISSUE DATE: February 26, 2025 MATURITY DATE: …
Open exhibit ↗EX-4.4 6 d863514dex44.htm EX-4.4 EX-4.4 Exhibit 4.4 CUSIP NO.: 478160 DD3 PRINCIPAL AMOUNT ISIN: XS3005214799 €[ ] Common Code: 300521479 REGISTERED NO. R- JOHNSON & JOHNSON 3.350% NOTE DUE 2037 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of The Bank of New York Depository (Nominees) Limited, or such other name as requested by an authorized representative of Euroclear or Clearstream (and any payment is made to its authorized nominee or to such other entity as is requested by an authorized representative of Euroclear or Clearstream), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL as the registered owner hereof, The Bank of New York Depository (Nominees) Limited, has an interest herein. The following summary of terms is subject to the information set forth on the reverse hereof: ORIGINAL ISSUE DATE: February 26, 2025 MATURITY DATE: …
Open exhibit ↗EX-4.5 7 d863514dex45.htm EX-4.5 EX-4.5 Exhibit 4.5 CUSIP NO.: 478160 DE1 PRINCIPAL AMOUNT ISIN: XS3005215093 €[ ] Common Code: 300521509 REGISTERED NO. R- JOHNSON & JOHNSON 3.600% NOTE DUE 2045 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of The Bank of New York Depository (Nominees) Limited, or such other name as requested by an authorized representative of Euroclear or Clearstream (and any payment is made to its authorized nominee or to such other entity as is requested by an authorized representative of Euroclear or Clearstream), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL as the registered owner hereof, The Bank of New York Depository (Nominees) Limited, has an interest herein. The following summary of terms is subject to the information set forth on the reverse hereof: ORIGINAL ISSUE DATE: February 26, 2025 MATURITY DATE: …
Open exhibit ↗EX-4.6 8 d863514dex46.htm EX-4.6 EX-4.6 Exhibit 4.6 CUSIP NO.: 478160 DF8 PRINCIPAL AMOUNT ISIN: XS3005215689 €[ ] Common Code: 300521568 REGISTERED NO. R- JOHNSON & JOHNSON 3.700% NOTE DUE 2055 Unless this certificate is presented by an authorized representative of Euroclear Bank S.A./N.V. (“Euroclear”) or Clearstream Banking, Societe Anonyme (“Clearstream”) to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of The Bank of New York Depository (Nominees) Limited, or such other name as requested by an authorized representative of Euroclear or Clearstream (and any payment is made to its authorized nominee or to such other entity as is requested by an authorized representative of Euroclear or Clearstream), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL as the registered owner hereof, The Bank of New York Depository (Nominees) Limited, has an interest herein. The following summary of terms is subject to the information set forth on the reverse hereof: ORIGINAL ISSUE DATE: February 26, 2025 M…
Open exhibit ↗